Biocryst Pharma Inc (BCRX)

$8.81 -0.17 (-1.89%)
Market Cap 2.28B
Revenue (ttm) 874.84M
Net Income (ttm) 263.86M
EPS (ttm) N/A
PE Ratio 7.11
Forward PE N/A
Profit Margin 30.16%
Debt to Equity Ratio -1.55
Volume 3,190,200
Avg Vol 4,716,354
Day's Range N/A - N/A
Shares Out 254.16M
Stochastic %K 4%
Beta 0.55
Analysts Strong Sell
Price Target $20.73

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 919 859 1302
Fax: 919 859 1314
Address:
4505 Emperor Boulevard, Suite 200, Durham, United States
Paulzk
Paulzk Aug. 4 at 12:57 PM
$BCRX BioCryst Pharmaceuticals (BCRX) is scheduled to release its second quarter 2026 financial results on August 5, 2026, with the earnings call starting at 8:30 AM EDT. You can track the event details and access webcasts directly through the BioCryst Investor Relations portal. https://ir.biocryst.com/
0 · Reply
Paulzk
Paulzk Aug. 4 at 12:48 PM
$BCRX Not much volume Trade in Pre-market (Until 9:28 AM ET) Biocryst PharmaceuticalsExtended hours price per share$8.86 +$0.05 (0.57%) Bid EDGX 8.85 x 1000 Ask XNMS 8.95 x 300 Volume 5,667
0 · Reply
2YrsEarly
2YrsEarly Aug. 4 at 2:12 AM
$BCRX Ask yourself why the smartest money (institutions) who are also the biggest short positions have been covering the past month?? Why did they cover 18m of 49m shares short at higher levels than we are at the close today? Remember they are in the know on coming news long before retail. What you’re seeing now is textbook market maker scumbag psychology to portray the illusion that bad news is coming in the ER. The short interest hasn’t been this low since pre-Astria acquisition announcement. And remember we have 15% more outstanding shares now. IMO and in conclusion the recent decline coupled with the large short interest covering tells you good news is coming and the stock is headed higher. The shorts are getting out of the way and COVERING during the illusion of weakness. Look back at spring ‘24 same thing happened with a huge decline in short interest and weak stock price followed by a massive rally from 6-11+. This is the exact same playbook!
2 · Reply
Stock_Catcher
Stock_Catcher Aug. 4 at 2:08 AM
Treasure Tuesday Watchlist- Bio Sector $DRTS $MLTX $ALT $REPL $BCRX
3 · Reply
Paulzk
Paulzk Aug. 3 at 11:49 PM
$BCRX Trump says he wants to give Iran "every last chance before decapitation"
1 · Reply
Paulzk
Paulzk Aug. 3 at 11:48 PM
$BCRX The U.S. military said on X Monday that it has redirected 44 commercial vessels under its blockade against Iran. U.S. forces have disabled two vessels and boarded another two, according to CENTCOM.
0 · Reply
Paulzk
Paulzk Aug. 3 at 11:47 PM
$BCRX More lies by DT Despite President Trump's continued comments that negotiations with Iran are set to begin on Monday, U.S. officials have told CBS News that there are no "new" or novel negotiations planned. Mr. Trump called Iran's leadership "unbelievably duplicitous" Monday after Iran said hours earlier it had no plans to hold direct talks with Washington, despite the U.S. leader's claim that negotiations would start today. https://www.cbsnews.com/live-updates/iran-war-donald-trump-us-denies-negotiations-begin-strikes-called-off/
0 · Reply
Citra182
Citra182 Aug. 3 at 10:55 PM
$BCRX wheres the guy with the moth and 9.50 image. We need him back...
1 · Reply
Fergus20
Fergus20 Aug. 3 at 9:39 PM
$BCRX what a terrible day
2 · Reply
Cap_00
Cap_00 Aug. 3 at 7:48 PM
$BCRX Such an undervalued stock.. Management is projecting 1.8B by 2033. 1B by 2030. Company is profitable in non-GAPP. They just shut down Alabama plant. Only oral of HAE and Navenibart is going to be the dominant player due to 3 and 6 month dosing.
1 · Reply
Latest News on BCRX
BioCryst to Report Second Quarter 2026 Financial Results on August 5

Jul 22, 2026, 7:00 AM EDT - 13 days ago

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BioCryst appoints David Jenkins as chief scientific officer

2026-07-15T11:10:48.000Z - 20 days ago

BioCryst appoints David Jenkins as chief scientific officer

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

Jul 15, 2026, 7:00 AM EDT - 20 days ago

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

BioCryst resumed with a Neutral at JPMorgan

2026-07-13T09:50:32.000Z - 22 days ago

BioCryst resumed with a Neutral at JPMorgan

BioCryst price target raised to $14 from $13 at RBC Capital

2026-07-07T11:20:35.000Z - 4 weeks ago

BioCryst price target raised to $14 from $13 at RBC Capital

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2026, 7:00 AM EDT - 4 weeks ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst price target raised to $29 from $27 at Cantor Fitzgerald

2026-06-30T11:35:29.000Z - 5 weeks ago

BioCryst price target raised to $29 from $27 at Cantor Fitzgerald

BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs

Jun 29, 2026, 8:21 AM EDT - 5 weeks ago

BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs

BioCryst to discontinue internal discovery programs, close Alabama facility

2026-06-29T11:21:00.000Z - 5 weeks ago

BioCryst to discontinue internal discovery programs, close Alabama facility

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

Jun 29, 2026, 7:00 AM EDT - 5 weeks ago

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

BioCryst to present new Orladeyo data at EAACI

2026-06-12T11:15:09.000Z - 7 weeks ago

BioCryst to present new Orladeyo data at EAACI

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

Jun 12, 2026, 7:00 AM EDT - 7 weeks ago

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 3:45 PM EDT - 2 months ago

BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

May 27, 2026, 7:00 AM EDT - 2 months ago

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BioCryst Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 4:40 PM EDT - 2 months ago

BioCryst Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

BioCryst price target raised to $28 from $25 at Citizens

2026-05-07T11:43:06.000Z - 3 months ago

BioCryst price target raised to $28 from $25 at Citizens

BioCryst reports Q1 EPS ($2.98), consensus 11c

2026-05-07T06:49:24.000Z - 3 months ago

BioCryst reports Q1 EPS ($2.98), consensus 11c

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2026

BioCryst Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

BioCryst Pharmaceuticals Earnings release: Q1 2026

BioCryst Pharmaceuticals Slides: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

BioCryst Pharmaceuticals Slides: Q1 2026

BioCryst Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

BioCryst Pharmaceuticals Quarterly report: Q1 2026

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 7:00 AM EDT - 3 months ago

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst enters navenibart license agreement with Neopharmed Gentili

2026-05-04T11:24:11.000Z - 3 months ago

BioCryst enters navenibart license agreement with Neopharmed Gentili

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

May 4, 2026, 7:00 AM EDT - 3 months ago

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst to Present at Upcoming Investor Conferences

Apr 28, 2026, 7:00 AM EDT - 3 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

BioCryst Pharmaceuticals Proxy statement: Proxy filing

BioCryst Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

BioCryst Pharmaceuticals Proxy statement: Proxy filing

BioCryst to Report First Quarter 2026 Financial Results on May 6

Apr 15, 2026, 7:00 AM EDT - 3 months ago

BioCryst to Report First Quarter 2026 Financial Results on May 6

BioCryst price target raised to $14 from $13 at RBC Capital

2026-04-07T15:13:58.000Z - 4 months ago

BioCryst price target raised to $14 from $13 at RBC Capital

BioCryst appoints Sandeep Menon as chief research and development officer

2026-04-06T11:05:55.000Z - 4 months ago

BioCryst appoints Sandeep Menon as chief research and development officer

ALNY

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

Apr 6, 2026, 7:00 AM EDT - 4 months ago

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

BioCryst reports inducement grants under Nasdaq listing rule

2026-03-04T12:08:31.000Z - 5 months ago

BioCryst reports inducement grants under Nasdaq listing rule

BioCryst Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:10 AM EST - 5 months ago

BioCryst Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

BioCryst price target raised to $22 from $21 at Wedbush

2026-03-02T13:53:06.000Z - 5 months ago

BioCryst price target raised to $22 from $21 at Wedbush

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2025

BioCryst Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

BioCryst Pharmaceuticals Annual report: Q4 2025

BioCryst Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

BioCryst Pharmaceuticals Earnings release: Q4 2025

BioCryst Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

BioCryst Pharmaceuticals Slides: Q4 2025

BioCryst reports Q4 EPS $1.12 vs (13c) last year

2026-02-26T12:19:23.000Z - 5 months ago

BioCryst reports Q4 EPS $1.12 vs (13c) last year

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 7:00 AM EST - 5 months ago

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

BioCryst to Present at Upcoming Investor Conference

Feb 17, 2026, 7:00 AM EST - 6 months ago

BioCryst to Present at Upcoming Investor Conference

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 11, 2026, 7:00 AM EST - 6 months ago

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

Feb 5, 2026, 7:01 AM EST - 6 months ago

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Jan 23, 2026, 9:00 AM EST - 6 months ago

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

BioCryst Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 7 months ago

BioCryst Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 7 months ago

BioCryst Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

Jan 12, 2026, 7:00 AM EST - 7 months ago

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 7 months ago

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

FDA expands approval of BioCryst's rare disease drug for use in young children

Dec 12, 2025, 7:06 AM EST - 8 months ago

FDA expands approval of BioCryst's rare disease drug for use in young children

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

Dec 12, 2025, 7:00 AM EST - 8 months ago

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Dec 3, 2025, 7:00 AM EST - 8 months ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

BioCryst Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 12:00 PM EST - 9 months ago

BioCryst Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Nov 6, 2025, 8:00 AM EST - 9 months ago

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 9 months ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2025

BioCryst Pharmaceuticals Quarterly report: Q3 2025

Nov 3, 2025, 8:30 AM EST - 9 months ago

BioCryst Pharmaceuticals Quarterly report: Q3 2025

BioCryst Pharmaceuticals Earnings release: Q3 2025

Nov 3, 2025, 8:30 AM EST - 9 months ago

BioCryst Pharmaceuticals Earnings release: Q3 2025

BioCryst Pharmaceuticals Slides: Q3 2025

Nov 3, 2025, 8:30 AM EST - 9 months ago

BioCryst Pharmaceuticals Slides: Q3 2025

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 7:00 AM EST - 9 months ago

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 23, 2025, 7:00 AM EDT - 10 months ago

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Oct 20, 2025, 7:00 AM EDT - 10 months ago

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Oct 17, 2025, 3:20 PM EDT - 10 months ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

ATXS

BioCryst Pharmaceuticals Transcript: M&A Announcement

Oct 14, 2025, 8:00 AM EDT - 10 months ago

BioCryst Pharmaceuticals Transcript: M&A Announcement

BioCryst Pharmaceuticals Press release: M&A Announcement

Oct 14, 2025, 8:00 AM EDT - 10 months ago

BioCryst Pharmaceuticals Press release: M&A Announcement

BioCryst Pharmaceuticals Slides: M&A Announcement

Oct 14, 2025, 8:00 AM EDT - 10 months ago

BioCryst Pharmaceuticals Slides: M&A Announcement

BioCryst to buy Astria Therapeutics in $700 million deal

Oct 14, 2025, 7:35 AM EDT - 10 months ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

Oct 14, 2025, 7:00 AM EDT - 10 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

ATXS

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Oct 1, 2025, 7:00 AM EDT - 10 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

BioCryst Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:45 AM EDT - 11 months ago

BioCryst Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

BioCryst Announces Departure of Dr. Helen Thackray

Aug 11, 2025, 7:00 AM EDT - 1 year ago

BioCryst Announces Departure of Dr. Helen Thackray

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2025

BioCryst Pharmaceuticals Quarterly report: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Quarterly report: Q2 2025

BioCryst Pharmaceuticals Earnings release: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Earnings release: Q2 2025

BioCryst Pharmaceuticals Slides: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Slides: Q2 2025

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 7:00 AM EDT - 1 year ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 31, 2025, 7:00 AM EDT - 1 year ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 21, 2025, 7:00 AM EDT - 1 year ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 9, 2025, 7:00 AM EDT - 1 year ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jul 7, 2025, 7:00 AM EDT - 1 year ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

BioCryst Pharmaceuticals Transcript: M&A Announcement

Jun 27, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: M&A Announcement

BioCryst Pharmaceuticals Press release: M&A Announcement

Jun 27, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Press release: M&A Announcement

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 27, 2025, 7:00 AM EDT - 1 year ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 16, 2025, 7:00 AM EDT - 1 year ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

ORLADEYO® (berotralstat) Approved in Colombia

Jun 13, 2025, 7:00 AM EDT - 1 year ago

ORLADEYO® (berotralstat) Approved in Colombia

BioCryst Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 8:40 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 6, 2025, 7:00 AM EDT - 1 year ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 4:55 PM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

Jun 2, 2025, 7:00 AM EDT - 1 year ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 30, 2025, 7:00 AM EDT - 1 year ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 16, 2025, 7:00 AM EDT - 1 year ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

BioCryst Pharmaceuticals Transcript: Bank of America 2025 Healthcare Conference

May 14, 2025, 1:40 PM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Bank of America 2025 Healthcare Conference

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 14, 2025, 7:00 AM EDT - 1 year ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

BioCryst Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2025

BioCryst Pharmaceuticals Quarterly report: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Quarterly report: Q1 2025

BioCryst Pharmaceuticals Earnings release: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Earnings release: Q1 2025

BioCryst Pharmaceuticals Slides: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Slides: Q1 2025

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 1 year ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst Appoints Steve Frank to Board of Directors

May 1, 2025, 7:00 AM EDT - 1 year ago

BioCryst Appoints Steve Frank to Board of Directors

BioCryst Pharmaceuticals Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioCryst Pharmaceuticals Proxy statement: Proxy Filing

BioCryst Pharmaceuticals Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioCryst Pharmaceuticals Proxy statement: Proxy Filing

BioCryst to Report First Quarter 2025 Financial Results on May 5

Apr 21, 2025, 7:00 AM EDT - 1 year ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

BioCryst Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 9, 2025, 9:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

BioCryst Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 10:00 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

BioCryst Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 9:10 AM EST - 1 year ago

BioCryst Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 24, 2025, 8:30 AM EST - 1 year ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2024

BioCryst Pharmaceuticals Annual report: Q4 2024

Feb 24, 2025, 8:30 AM EST - 1 year ago

BioCryst Pharmaceuticals Annual report: Q4 2024

BioCryst Pharmaceuticals Earnings release: Q4 2024

Feb 24, 2025, 8:30 AM EST - 1 year ago

BioCryst Pharmaceuticals Earnings release: Q4 2024

BioCryst Pharmaceuticals Slides: Q4 2024

Feb 24, 2025, 8:30 AM EST - 1 year ago

BioCryst Pharmaceuticals Slides: Q4 2024

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Feb 24, 2025, 7:00 AM EST - 1 year ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Paulzk
Paulzk Aug. 4 at 12:57 PM
$BCRX BioCryst Pharmaceuticals (BCRX) is scheduled to release its second quarter 2026 financial results on August 5, 2026, with the earnings call starting at 8:30 AM EDT. You can track the event details and access webcasts directly through the BioCryst Investor Relations portal. https://ir.biocryst.com/
0 · Reply
Paulzk
Paulzk Aug. 4 at 12:48 PM
$BCRX Not much volume Trade in Pre-market (Until 9:28 AM ET) Biocryst PharmaceuticalsExtended hours price per share$8.86 +$0.05 (0.57%) Bid EDGX 8.85 x 1000 Ask XNMS 8.95 x 300 Volume 5,667
0 · Reply
2YrsEarly
2YrsEarly Aug. 4 at 2:12 AM
$BCRX Ask yourself why the smartest money (institutions) who are also the biggest short positions have been covering the past month?? Why did they cover 18m of 49m shares short at higher levels than we are at the close today? Remember they are in the know on coming news long before retail. What you’re seeing now is textbook market maker scumbag psychology to portray the illusion that bad news is coming in the ER. The short interest hasn’t been this low since pre-Astria acquisition announcement. And remember we have 15% more outstanding shares now. IMO and in conclusion the recent decline coupled with the large short interest covering tells you good news is coming and the stock is headed higher. The shorts are getting out of the way and COVERING during the illusion of weakness. Look back at spring ‘24 same thing happened with a huge decline in short interest and weak stock price followed by a massive rally from 6-11+. This is the exact same playbook!
2 · Reply
Stock_Catcher
Stock_Catcher Aug. 4 at 2:08 AM
Treasure Tuesday Watchlist- Bio Sector $DRTS $MLTX $ALT $REPL $BCRX
3 · Reply
Paulzk
Paulzk Aug. 3 at 11:49 PM
$BCRX Trump says he wants to give Iran "every last chance before decapitation"
1 · Reply
Paulzk
Paulzk Aug. 3 at 11:48 PM
$BCRX The U.S. military said on X Monday that it has redirected 44 commercial vessels under its blockade against Iran. U.S. forces have disabled two vessels and boarded another two, according to CENTCOM.
0 · Reply
Paulzk
Paulzk Aug. 3 at 11:47 PM
$BCRX More lies by DT Despite President Trump's continued comments that negotiations with Iran are set to begin on Monday, U.S. officials have told CBS News that there are no "new" or novel negotiations planned. Mr. Trump called Iran's leadership "unbelievably duplicitous" Monday after Iran said hours earlier it had no plans to hold direct talks with Washington, despite the U.S. leader's claim that negotiations would start today. https://www.cbsnews.com/live-updates/iran-war-donald-trump-us-denies-negotiations-begin-strikes-called-off/
0 · Reply
Citra182
Citra182 Aug. 3 at 10:55 PM
$BCRX wheres the guy with the moth and 9.50 image. We need him back...
1 · Reply
Fergus20
Fergus20 Aug. 3 at 9:39 PM
$BCRX what a terrible day
2 · Reply
Cap_00
Cap_00 Aug. 3 at 7:48 PM
$BCRX Such an undervalued stock.. Management is projecting 1.8B by 2033. 1B by 2030. Company is profitable in non-GAPP. They just shut down Alabama plant. Only oral of HAE and Navenibart is going to be the dominant player due to 3 and 6 month dosing.
1 · Reply
mykhalifa
mykhalifa Aug. 3 at 7:48 PM
$BCRX this is the only thing red on my watchlist that has over 50 tickers 😂
1 · Reply
buy_undervalued_stocks
buy_undervalued_stocks Aug. 3 at 7:06 PM
$BCRX Another wonderful day being a BCRX shareholder!!! Compliments of your PATHETIC Management team and Board...
1 · Reply
jmartin795
jmartin795 Aug. 3 at 6:33 PM
$BCRX My dog has fleas. 😆
0 · Reply
Cello69
Cello69 Aug. 3 at 5:41 PM
$BCRX When will the fuckery end ?
2 · Reply
SpencerF
SpencerF Aug. 3 at 5:33 PM
$BCRX just a bad company? Or is it all from the price knobs at the hedge fund offices being messed with?
1 · Reply
Fergus20
Fergus20 Aug. 3 at 4:59 PM
$BCRX so pathetic
1 · Reply
DontBanMeAgain
DontBanMeAgain Aug. 3 at 4:53 PM
$BCRX Sept 11s, eh? Something tells me the CRWV and SNDK calls might do better...but ya never know.
0 · Reply
Paulzk
Paulzk Aug. 3 at 4:17 PM
$BCRX Death by a thousand cuts.
0 · Reply
drose0527
drose0527 Aug. 3 at 4:14 PM
$BCRX as I posted earlier. About an hour ago. This next move BCRX makes will likely be a mirror effect of that 2 month sell off from 10.32 to 8.45. This will be a run from 8.80/9.00 to 12.11 in about the same time frame. So this will mostly feel very stagnant in this process. If company doesn’t have anything out standing in this earnings report. But that’s how I see the chart playing out. But should end the year in December around that 12.11
1 · Reply
St0ckt0k101
St0ckt0k101 Aug. 3 at 4:12 PM
$BCRX loading 🆙 in the next month here AFTER EARNINGS. No way this doesn’t get bought out within the next year or so. Enough is enough here. If this goes anywhere near $8 or below after earnings I am buying all I can.
1 · Reply
drose0527
drose0527 Aug. 3 at 3:40 PM
$BCRX looks like next landing spot for this will be right around 12.11. Should look to compress here in this range as I said between 8.90-9.10 until Wednesday.
0 · Reply
Cap_00
Cap_00 Aug. 3 at 3:06 PM
$BCRX one of my favs.. not trading well though. I just added. They're streamlining their operations by closing Alabama plant. Bigger midcap/BP should be eyeing this.. 3B peak sales and leader in HAE.
3 · Reply